
Angela Y. Ortiz
Supervisory Patent Examiner (ID: 10236, Phone: (571)272-1206 , Office: P/1741 )
| Most Active Art Unit | 1732 |
| Art Unit(s) | 1307, 1732, 1789, 1797, 1798, 2899, 3663 |
| Total Applications | 1098 |
| Issued Applications | 802 |
| Pending Applications | 55 |
| Abandoned Applications | 242 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20083706
[patent_doc_number] => 20250213642
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-03
[patent_title] => SENESCENCE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 19/082426
[patent_app_country] => US
[patent_app_date] => 2025-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19082426
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/082426 | SENESCENCE INHIBITOR | Mar 17, 2025 | Pending |
Array
(
[id] => 20014451
[patent_doc_number] => 20250152673
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-15
[patent_title] => PHARMACEUTICAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 19/026842
[patent_app_country] => US
[patent_app_date] => 2025-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19026842
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/026842 | PHARMACEUTICAL FORMULATIONS | Jan 16, 2025 | Pending |
Array
(
[id] => 19890327
[patent_doc_number] => 20250115639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-10
[patent_title] => HANGTAIMYCIN DERIVATIVES AND THEIR PREPARATION METHODS AND APPLICATION
[patent_app_type] => utility
[patent_app_number] => 18/955985
[patent_app_country] => US
[patent_app_date] => 2024-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7177
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18955985
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/955985 | Hangtaimycin derivatives and their preparation methods and application | Nov 21, 2024 | Issued |
Array
(
[id] => 19830936
[patent_doc_number] => 20250082722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH)
[patent_app_type] => utility
[patent_app_number] => 18/954145
[patent_app_country] => US
[patent_app_date] => 2024-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65403
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18954145
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/954145 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Nov 19, 2024 | Pending |
Array
(
[id] => 19969682
[patent_doc_number] => 12338274
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 18/917707
[patent_app_country] => US
[patent_app_date] => 2024-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 63487
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917707
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/917707 | Anti-VEGF protein compositions and methods for producing the same | Oct 15, 2024 | Issued |
Array
(
[id] => 19692840
[patent_doc_number] => 20250011385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => Long-Acting GLP-1 Compound
[patent_app_type] => utility
[patent_app_number] => 18/883592
[patent_app_country] => US
[patent_app_date] => 2024-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18883592
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/883592 | Long-Acting GLP-1 Compound | Sep 11, 2024 | Abandoned |
Array
(
[id] => 19554922
[patent_doc_number] => 20240366714
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/774846
[patent_app_country] => US
[patent_app_date] => 2024-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13965
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18774846
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/774846 | Compositions and methods for the treatment of metabolic and liver disorders | Jul 15, 2024 | Issued |
Array
(
[id] => 19692894
[patent_doc_number] => 20250011439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/742845
[patent_app_country] => US
[patent_app_date] => 2024-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742845
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/742845 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | Jun 12, 2024 | Pending |
Array
(
[id] => 19948381
[patent_doc_number] => 12319728
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 18/637124
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 63688
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637124
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637124 | Anti-VEGF protein compositions and methods for producing the same | Apr 15, 2024 | Issued |
Array
(
[id] => 19656985
[patent_doc_number] => 20240424050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXA
[patent_app_type] => utility
[patent_app_number] => 18/626600
[patent_app_country] => US
[patent_app_date] => 2024-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20712
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626600
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/626600 | Systems and methods for treatment of hearing using dihexa | Apr 3, 2024 | Issued |
Array
(
[id] => 19473878
[patent_doc_number] => 12103954
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-01
[patent_title] => Heterodimeric Fc cytokines and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/582180
[patent_app_country] => US
[patent_app_date] => 2024-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 48
[patent_no_of_words] => 51947
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18582180
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/582180 | Heterodimeric Fc cytokines and uses thereof | Feb 19, 2024 | Issued |
Array
(
[id] => 19784237
[patent_doc_number] => 20250057916
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => TREATMENT OF AGE-RELATED MACULAR DEGENERATION
[patent_app_type] => utility
[patent_app_number] => 18/436212
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9062
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436212
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436212 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Feb 7, 2024 | Pending |
Array
(
[id] => 19318361
[patent_doc_number] => 20240239904
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/415415
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18415415
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/415415 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | Jan 16, 2024 | Pending |
Array
(
[id] => 20343151
[patent_doc_number] => 12466873
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Modified anti-inflammatory proteins and method of use
[patent_app_type] => utility
[patent_app_number] => 18/414112
[patent_app_country] => US
[patent_app_date] => 2024-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 14
[patent_no_of_words] => 8875
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414112
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/414112 | Modified anti-inflammatory proteins and method of use | Jan 15, 2024 | Issued |
Array
(
[id] => 19769963
[patent_doc_number] => 20250051389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => AROMATIC-CATIONIC PEPTIDES AND USES OF SAME
[patent_app_type] => utility
[patent_app_number] => 18/404263
[patent_app_country] => US
[patent_app_date] => 2024-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14925
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18404263
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/404263 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | Jan 3, 2024 | Pending |
Array
(
[id] => 19521110
[patent_doc_number] => 12122818
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Insulin analogues and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/541682
[patent_app_country] => US
[patent_app_date] => 2023-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 16613
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541682
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/541682 | Insulin analogues and uses thereof | Dec 14, 2023 | Issued |
Array
(
[id] => 19345199
[patent_doc_number] => 20240254162
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => CYCLOTHEONELLAZOLEA, AND SYNTHETIC METHOD THEREFOR, AND APPLICATION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/527402
[patent_app_country] => US
[patent_app_date] => 2023-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18527402
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/527402 | CYCLOTHEONELLAZOLEA, AND SYNTHETIC METHOD THEREFOR, AND APPLICATION METHOD THEREOF | Dec 3, 2023 | Pending |
Array
(
[id] => 19586387
[patent_doc_number] => 20240383944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 18/526685
[patent_app_country] => US
[patent_app_date] => 2023-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25050
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18526685
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/526685 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | Nov 30, 2023 | Pending |
Array
(
[id] => 19904339
[patent_doc_number] => 12281335
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-22
[patent_title] => Methods and compositions for delivery of viral vectors across the blood-brain barrier
[patent_app_type] => utility
[patent_app_number] => 18/518000
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 45
[patent_no_of_words] => 33114
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518000
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/518000 | Methods and compositions for delivery of viral vectors across the blood-brain barrier | Nov 21, 2023 | Issued |
Array
(
[id] => 19738321
[patent_doc_number] => 12215139
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Preparation method and application of high-purity plant-derived recombinant human serum albumin
[patent_app_type] => utility
[patent_app_number] => 18/518227
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 10098
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 471
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518227
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/518227 | Preparation method and application of high-purity plant-derived recombinant human serum albumin | Nov 21, 2023 | Issued |